Cargando…

Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee

SIMPLE SUMMARY: Radical nephroureterectomy (RNU) is the standard treatment for high-risk upper tract urothelial carcinoma (UTUC). It implies significant reduction in the renal function, compromising adjuvant chemotherapy administration and leading to risk of end stage renal disease in frail patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Masson-Lecomte, Alexandra, Vaillant, Victoire, Roumiguié, Mathieu, Lévy, Stéphan, Pradère, Benjamin, Peyromaure, Michaël, Duquesne, Igor, De La Taille, Alexandre, Lebâcle, Cédric, Panis, Adrien, Traxer, Olivier, Leon, Priscilla, Hulin, Maud, Xylinas, Evanguelos, Audenet, François, Seisen, Thomas, Loriot, Yohann, Allory, Yves, Rouprêt, Morgan, Neuzillet, Yann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656759/
https://www.ncbi.nlm.nih.gov/pubmed/36358870
http://dx.doi.org/10.3390/cancers14215452
_version_ 1784829518067793920
author Masson-Lecomte, Alexandra
Vaillant, Victoire
Roumiguié, Mathieu
Lévy, Stéphan
Pradère, Benjamin
Peyromaure, Michaël
Duquesne, Igor
De La Taille, Alexandre
Lebâcle, Cédric
Panis, Adrien
Traxer, Olivier
Leon, Priscilla
Hulin, Maud
Xylinas, Evanguelos
Audenet, François
Seisen, Thomas
Loriot, Yohann
Allory, Yves
Rouprêt, Morgan
Neuzillet, Yann
author_facet Masson-Lecomte, Alexandra
Vaillant, Victoire
Roumiguié, Mathieu
Lévy, Stéphan
Pradère, Benjamin
Peyromaure, Michaël
Duquesne, Igor
De La Taille, Alexandre
Lebâcle, Cédric
Panis, Adrien
Traxer, Olivier
Leon, Priscilla
Hulin, Maud
Xylinas, Evanguelos
Audenet, François
Seisen, Thomas
Loriot, Yohann
Allory, Yves
Rouprêt, Morgan
Neuzillet, Yann
author_sort Masson-Lecomte, Alexandra
collection PubMed
description SIMPLE SUMMARY: Radical nephroureterectomy (RNU) is the standard treatment for high-risk upper tract urothelial carcinoma (UTUC). It implies significant reduction in the renal function, compromising adjuvant chemotherapy administration and leading to risk of end stage renal disease in frail patients. Distal ureterectomy (DU) might be an alternative for tumors of the distal ureter but its indications remain unclear mainly due to concern about potential upper tract recurrences. The objective of our retrospective study was to determine the oncologic outcomes of DU for high-risk UTUC of the pelvic ureter, and to assess factors associated with recurrence in the particular population. We showed that oncological outcomes after DU were similar to those after RNU. Some of the classical prognostic factors after RNU were not identified in this cohort, pinpointing the necessity to consider tumors of the distal ureter as a specific entity. ABSTRACT: Upper urinary tract urothelial carcinoma (UTUC) is an uncommon disease and its gold-standard treatment is radical nephroureterectomy (RNU). Distal ureterectomy (DU) might be an alternative for tumors of the distal ureter but its indications remain unclear. Here, we aimed to evaluate the oncological outcomes of DU for UTUC of the pelvic ureter. We performed a multicenter retrospective analysis of patients with UTUC who underwent DU. The primary endpoint was 5-year cancer-specific survival (CSS), followed by overall survival (OS), intravesical recurrence-free (IVR) and homolateral urinary tract recurrence-free (HUR) survivals as secondary endpoints. Univariate and multivariate Cox regressions were performed to assess factors associated with outcomes. 155 patients were included, 91% of which were high-risk. 5-year CSS was 84.4%, OS was 71.9%, IVR-free survival was 43.6% and HUR-free survival was 74.4%. Multifocality, high grade and tumor size were the most significant predictors of survival endpoints. Of note, neither hydronephrosis nor pre-operative diagnostic ureteroscopy/JJ stent were associated with any of the endpoints. Perioperative morbidity was minimal. In conclusion, DU stands as a possible alternative to RNU for UTUC of the pelvic ureter. Close monitoring is mandatory due to the high risk of recurrence in the remaining urinary tract.
format Online
Article
Text
id pubmed-9656759
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96567592022-11-15 Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee Masson-Lecomte, Alexandra Vaillant, Victoire Roumiguié, Mathieu Lévy, Stéphan Pradère, Benjamin Peyromaure, Michaël Duquesne, Igor De La Taille, Alexandre Lebâcle, Cédric Panis, Adrien Traxer, Olivier Leon, Priscilla Hulin, Maud Xylinas, Evanguelos Audenet, François Seisen, Thomas Loriot, Yohann Allory, Yves Rouprêt, Morgan Neuzillet, Yann Cancers (Basel) Article SIMPLE SUMMARY: Radical nephroureterectomy (RNU) is the standard treatment for high-risk upper tract urothelial carcinoma (UTUC). It implies significant reduction in the renal function, compromising adjuvant chemotherapy administration and leading to risk of end stage renal disease in frail patients. Distal ureterectomy (DU) might be an alternative for tumors of the distal ureter but its indications remain unclear mainly due to concern about potential upper tract recurrences. The objective of our retrospective study was to determine the oncologic outcomes of DU for high-risk UTUC of the pelvic ureter, and to assess factors associated with recurrence in the particular population. We showed that oncological outcomes after DU were similar to those after RNU. Some of the classical prognostic factors after RNU were not identified in this cohort, pinpointing the necessity to consider tumors of the distal ureter as a specific entity. ABSTRACT: Upper urinary tract urothelial carcinoma (UTUC) is an uncommon disease and its gold-standard treatment is radical nephroureterectomy (RNU). Distal ureterectomy (DU) might be an alternative for tumors of the distal ureter but its indications remain unclear. Here, we aimed to evaluate the oncological outcomes of DU for UTUC of the pelvic ureter. We performed a multicenter retrospective analysis of patients with UTUC who underwent DU. The primary endpoint was 5-year cancer-specific survival (CSS), followed by overall survival (OS), intravesical recurrence-free (IVR) and homolateral urinary tract recurrence-free (HUR) survivals as secondary endpoints. Univariate and multivariate Cox regressions were performed to assess factors associated with outcomes. 155 patients were included, 91% of which were high-risk. 5-year CSS was 84.4%, OS was 71.9%, IVR-free survival was 43.6% and HUR-free survival was 74.4%. Multifocality, high grade and tumor size were the most significant predictors of survival endpoints. Of note, neither hydronephrosis nor pre-operative diagnostic ureteroscopy/JJ stent were associated with any of the endpoints. Perioperative morbidity was minimal. In conclusion, DU stands as a possible alternative to RNU for UTUC of the pelvic ureter. Close monitoring is mandatory due to the high risk of recurrence in the remaining urinary tract. MDPI 2022-11-06 /pmc/articles/PMC9656759/ /pubmed/36358870 http://dx.doi.org/10.3390/cancers14215452 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Masson-Lecomte, Alexandra
Vaillant, Victoire
Roumiguié, Mathieu
Lévy, Stéphan
Pradère, Benjamin
Peyromaure, Michaël
Duquesne, Igor
De La Taille, Alexandre
Lebâcle, Cédric
Panis, Adrien
Traxer, Olivier
Leon, Priscilla
Hulin, Maud
Xylinas, Evanguelos
Audenet, François
Seisen, Thomas
Loriot, Yohann
Allory, Yves
Rouprêt, Morgan
Neuzillet, Yann
Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee
title Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee
title_full Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee
title_fullStr Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee
title_full_unstemmed Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee
title_short Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee
title_sort oncological outcomes of distal ureterectomy for high-risk urothelial carcinoma: a multicenter study by the french bladder cancer committee
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656759/
https://www.ncbi.nlm.nih.gov/pubmed/36358870
http://dx.doi.org/10.3390/cancers14215452
work_keys_str_mv AT massonlecomtealexandra oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT vaillantvictoire oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT roumiguiemathieu oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT levystephan oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT praderebenjamin oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT peyromauremichael oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT duquesneigor oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT delataillealexandre oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT lebaclecedric oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT panisadrien oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT traxerolivier oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT leonpriscilla oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT hulinmaud oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT xylinasevanguelos oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT audenetfrancois oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT seisenthomas oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT loriotyohann oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT alloryyves oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT roupretmorgan oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee
AT neuzilletyann oncologicaloutcomesofdistalureterectomyforhighriskurothelialcarcinomaamulticenterstudybythefrenchbladdercancercommittee